Exo-Top, NurExone’s wholly owned U.S. Subsidiary, Enters Into Binding MOU For Naïve Exosome Distribution in Mexico

Exo-Top Signs MOU for Naïve Exosome Distribution in Mexico

NurExone Biologic Inc.'s U.S. subsidiary, Exo-Top Inc., has entered a binding Memorandum of Understanding (MOU) with ExoLyra LLC for the exclusive distribution of naïve MSC-derived exosome products in Mexico. This agreement establishes Exo-Top's first structured commercial foothold, aiming to monetize its exosome capabilities in the medical wellness, aesthetics, and regenerative-health markets. The MOU outlines key commercial terms, including an upfront exclusivity fee of US$180,000, minimum purchase commitments starting at 20,000 units for the first 18 months, and ExoLyra's commitment to fund initial distribution activities with no less than US$800,000. The deal also includes preferential negotiation rights for Brazil and Panama, positioning Mexico as a strategic entry point into Latin America.

• The MOU provides Exo-Top with an exclusive distribution framework in Mexico, a strategic entry point into Latin America due to its sizable domestic market and established private medical ecosystem. The agreement also includes preferential negotiation rights for Brazil and Panama, indicating a broader regional expansion strategy for NurExone's commercial exosome products.
• The agreement includes significant financial commitments, such as a non-refundable territorial exclusivity fee of US$180,000 payable to Exo-Top. ExoLyra is also committed to funding initial distribution and market penetration activities with at least US$800,000 and will adhere to annual minimum purchase commitments, starting with 20,000 units in the first 18 months, to maintain exclusivity.
• The agreement centers on naïve MSC-derived exosome products, which are gaining traction in medical wellness, aesthetics, and regenerative health due to their natural role in cellular communication. This commercialization effort through Exo-Top complements NurExone's long-term therapeutic value creation strategy, which involves regulated development of loaded exosome-based drug candidates like ExoPTEN for CNS injuries.

Unmet Needs Driving the Medical Wellness and Regenerative Health Market

The medical wellness, aesthetics, and regenerative health sectors are increasingly converging around a shared imperative: addressing the consequences of global demographic aging and the inadequacy of conventional therapeutic models to arrest or reverse chronic degenerative disease. The shift from lifespan extension toward healthspan optimization has emerged as the central organizing principle across clinical, commercial, and regulatory dimensions. Below are the key unmet needs and target populations identified across the literature from 2024–2026.

• Aging populations with chronic degenerative disease: With the global elderly population projected to reach 2.1 billion by 2050, musculoskeletal conditions — including osteoarthritis, osteoporosis, sarcopenia, and degenerative disc disease — represent a growing and underserved disease burden. In the U.S. alone, musculoskeletal diseases affect over 121 million individuals and account for the highest disability rate among all disease categories. Traditional conservative and surgical interventions primarily alleviate symptoms without halting or reversing underlying degeneration, creating a clear unmet need for disease-modifying regenerative strategies.

• Patients with neurodegenerative and rare diseases: Populations with neurodegenerative conditions — characterized by progressive loss of neuronal and glial structure and function — face limited therapeutic options and impose high socioeconomic costs on patients, families, and healthcare systems. Similarly, patients with orphan and rare diseases, for whom no approved treatments exist, remain a priority target for advanced therapies including gene therapy and cell-based interventions, with numerous clinical trials currently ongoing worldwide.

• Elderly patients with impaired autologous regenerative capacity: The regenerative potential of stem cells decreases significantly with donor age and deteriorating health status, directly compromising the efficacy of autologous cell therapies in older patients — the very population with the greatest therapeutic need. Alternative strategies to restore age- and disease-depleted stem cell function, including cell-free secretome-based products and partial cellular reprogramming, are being actively explored as compensatory approaches.

• Patients with peripheral nerve injury (PNI) and peripheral artery disease: PNI represents a prevalent and functionally debilitating disorder resulting from trauma, immune dysregulation, and genetic factors, with existing repair modalities limited by donor scarcity, poor outcomes in long-segment defects, and low functional recovery rates. Peripheral artery disease is similarly emerging as a target for next-generation mRNA-LNP platforms, with ETV2 mRNA delivered via lipid nanoparticles demonstrating therapeutic potential in preclinical hindlimb ischemia models.

• Cancer patients and those with serious hematologic conditions: Cell therapy development — exemplified by the FDA approval of CD19 chimeric antigen receptor T-cell products in 2017 — has established a regulatory and clinical precedent for engineered cellular interventions in oncology, with continued pipeline expansion targeting hematologic and solid tumor indications.

• Aesthetics patients across the psychosocial spectrum: Aesthetic medicine is contending with a dual challenge: rising patient demand accompanied by regulatory fragmentation and ethical concerns around commercialization. Notably, approximately 83% of surveyed respondents — regardless of prior engagement with aesthetic treatments — acknowledged their emotional benefits, including improved self-confidence, underscoring the psychological dimension of unmet need in this population. Older adults aged 50–80 years represent a previously underrepresented cohort in aesthetic medicine research, with growing relevance as regenerative biostimulatory approaches (e.g., exosomes, biopolymers) are applied in dermatology.

• Patients with inflammatory and autoimmune conditions: Inflammatory bowel disease, autoimmune disorders, and chronic wounds represent conditions where current therapies enhance healing without achieving full tissue regeneration. Human intestinal organoid platforms are being developed as tools for mechanistic study and personalized therapy design, while secretome-based products are demonstrating regenerative activity across osteoarthritis, chronic wound, and neurological indications in preclinical and early clinical settings.

• Workforce and infrastructure gaps in regenerative medicine delivery: A structural unmet need exists at the systems level: the field faces a shortage of highly specialized professionals, with demand concentrated in QA/QC and regulatory affairs rather than technical cell culture roles. The establishment of robust public and academic education systems for regenerative medicine practitioners is identified as an urgent priority for sustainable clinical translation.

Exploring Broader Applications of NurExone's Exosome Platform

Naïve MSC-derived exosome products are being investigated across a broad and expanding range of indications beyond wellness and aesthetics, reflecting the platform's versatility in modulating inflammation, promoting tissue regeneration, and delivering therapeutic cargo. Intervention models span topical administration, scaffold-integrated delivery systems, and systemic cell-free approaches, with evidence drawn from preclinical studies and early-phase clinical investigations.

• Hair restoration (alopecia): Topical application of adipose-derived stem cell exosomes (ADSC-Exo) was evaluated in 39 androgenetic alopecia patients, demonstrating significant increases in hair density and thickness with no significant adverse reactions reported. Preclinical studies across 15 models further support efficacy in androgenetic alopecia, alopecia areata, and chemotherapy-induced alopecia, with mechanistic activity linked to Wnt/β-catenin, VEGF, and PI3K/AKT signalling and promotion of the telogen-to-anagen follicular transition.

• Neurodegenerative disorders: MSC-derived exosomes are under investigation for amyotrophic lateral sclerosis (ALS), with preclinical studies demonstrating beneficial effects on neurite growth and morphology in both wild-type and SOD1 transgenic primary motor neurons. Gene expression profiling has identified antioxidant and anti-inflammatory transcripts, and miRNA cargo capable of regulating antioxidant and anti-apoptotic pathways. MSC-EVs are also being explored for mild cognitive impairment (MCI) and Alzheimer's disease, leveraging their documented capacity to cross the blood-brain barrier and deliver therapeutic cargo.

• Acute lung injury (ALI) and acute respiratory distress syndrome (ARDS): Phase I and II clinical trials are currently underway internationally for MSC administration in ALI, with MSC-EVs being evaluated in preclinical models for ALI and other inflammatory lung diseases where no effective pharmacotherapy currently exists.

• Myocardial infarction (MI): EVs derived from adipose-derived stem cells have demonstrated therapeutic promise, with engineered ADSC-derived nanovesicles loaded with melatonin reducing cell apoptosis from 42.59 ± 2.69% to 13.88 ± 1.77% under ischaemia-mimic conditions. Scaffold-based delivery using 3D constructs has also shown improvements in cardiac tissue structure and function.

• Acute kidney injury (AKI): EVs are being evaluated as a superior alternative to MSC-based therapies across multiple preclinical models of ischaemia/reperfusion injury, renal toxic injury, and sepsis-induced AKI.

• Pulmonary fibrosis: Induced pluripotent stem cell MSC-derived EVs (iMSC-EVs) significantly reduced Ashcroft fibrosis scores and bronchoalveolar lavage fluid protein levels in a bleomycin-induced pulmonary fibrosis mouse model, with therapeutic efficacy comparable to primary MSC-EVs.

• Moderate psoriasis: Topically applied MSC-EVs modulate cutaneous inflammation via CD59-mediated inhibition of complement terminal component C5b-9 complex formation, reducing neutrophil infiltration and lowering IL-17 and IL-23 expression in psoriatic lesions. Preclinical and early clinical data suggest restoration of local immune homeostasis through paracrine extracellular mechanisms without systemic absorption or adverse effects.

• Anti-aging therapy: MSC-EVs have demonstrated efficacy in naturally aged human dermal fibroblast models, significantly reducing senescence-associated β-galactosidase, matrix metallopeptidase 1, P21, and IL-1β, while increasing collagen I levels. In vivo, MSC-EVs improved D-galactose-induced subacute aging in mice, ameliorating histopathological changes, oxidative stress, and aging-related gene expression.

• Additional unmet-need indications in preclinical development: MSC-EVs have been identified for investigation in critical-size bone defects, epidermolysis bullosa, spinal cord injury, corneal pathologies, and cartilage repair, with intervention models including scaffold-based delivery systems such as hydrogels, electrospun nanofibers, and 3D-printed constructs employing surface adsorption, hydrogel embedding, microsphere encapsulation, and lyophilisation strategies.

Exosomes' Commercial Dawn: Opportunity in a Regulatory Gray Zone

The recent distribution agreement for naïve MSC-derived exosome products in Mexico signals a pivotal moment for the burgeoning field of regenerative medicine, particularly within the medical wellness and aesthetics sectors. This move represents a strategic commercial entry point into Latin America, capitalizing on the growing global interest in advanced biologics. Mesenchymal stem cell (MSC)-derived exosomes are increasingly recognized as a powerful new therapeutic tool, offering a cell-free alternative to traditional stem cell therapies. Research indicates that these nanoscale vesicles carry bioactive molecules that can modulate cellular communication, reduce inflammation, and promote tissue regeneration, with potential applications ranging from skin repair to musculoskeletal healing. Their advantages, including lower immunogenicity and easier storage compared to live cells, make them attractive for broader commercialization.

However, this exciting commercial frontier is not without its complexities. The rapid growth of direct-to-consumer businesses offering secretome-based therapies often outpaces the development of comprehensive regulatory frameworks. This creates a 'gray zone' where product standardization, quality control, and robust clinical evidence for efficacy and long-term safety can be inconsistent. While preclinical studies show promise, the translation of these findings into validated clinical practice, especially for aesthetic and wellness applications, requires rigorous investigation. Companies entering this space must navigate challenges related to:

• Regulatory Scrutiny: The potential for increased oversight as regulatory bodies globally work to establish clear guidelines for exosome products.

• Product Standardization: Ensuring consistent quality, purity, and potency across batches, which is critical for reproducible therapeutic outcomes and patient safety.

• Clinical Validation: The ongoing need for robust clinical trials to definitively establish efficacy and long-term safety profiles for specific indications.

Ultimately, while this distribution deal marks a significant step towards monetizing exosome capabilities, the long-term success and credibility of such ventures will hinge on a commitment to scientific rigor, transparent data, and proactive engagement with evolving regulatory landscapes to ensure patient safety and build trust in these innovative therapies.